{"id":"W4365512242","doi":"10.1158/1538-7445.am2023-ct174","title":"Abstract CT174: First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Pharmacodynamics; Cancer; Oncology; Internal medicine; Pharmacokinetics; Immunotherapy; Antibody; Adverse effect; Pharmacology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001038912,0.0009663501,0.0009124476,0.0003528166,0.0003103657,0.0007503325,0.0005162351,0.0007748374,0.007219594],"category_scores_gemma":[0.0007907309,0.0002505892,0.0008517507,0.0002905035,0.0003385226,0.0004197623,0.0003334513,0.002396037,0.001376064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006849467,"about_ca_system_score_gemma":0.001268168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008152886,"about_ca_topic_score_gemma":0.002388976,"domain_scores_codex":[0.999756,0.0001094498,0.0000121865,0.00003749621,0.00004042292,0.00004443283],"domain_scores_gemma":[0.9995872,0.00006600305,0.00007329899,0.00003030255,0.00003607891,0.0002070744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4295375,0.05242978,0.02004823,0.003333019,0.003569084,0.0007455093,0.0003676719,0.006297231,0.1103045,0.0005913639,0.03557826,0.3371978],"study_design_scores_gemma":[0.3786296,0.5415537,0.03538097,0.0002626809,0.001653703,0.001160511,0.0000914499,0.001773553,0.01616406,0.0004913184,0.02278117,0.0000572584],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679374,0.01071126,0.001219348,0.001249154,0.000236527,0.003858402,0.007221258,0.0003411681,0.007225515],"genre_scores_gemma":[0.9664895,0.005362065,0.003297031,0.002131941,0.0002801012,0.002538101,0.0119613,0.00008163041,0.007858346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007219594,"threshold_uncertainty_score":0.02415192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04987680613467357,"score_gpt":0.4245616367554918,"score_spread":0.3746848306208183,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}